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Essentials
• The role of statins in hemostasis and venous throm-
boembolism (VTE) prophylaxis is not clear.
• This trial assessed whether rosuvastatin use affects
thrombin generation in patients with VTE.
• Endogenous thrombin potential and peak were
decreased by 10% and 5% with rosuvastatin therapy.
• These results provide basis for trials on the efficacy of
statins in reducing recurrent VTE risk.
Summary. Background: Statin therapy could form an
alternative prophylactic treatment for venous thromboem-
bolism (VTE) if statins are proven to downregulate
hemostasis and prevent recurrent VTE, without increasing
bleeding risk. Objectives: The STAtins Reduce Throm-
bophilia (START) trial investigated whether statin affects
coagulation in patients with prior VTE. Patients/meth-
ods: After anticoagulation withdrawal, patients were ran-
domized to rosuvastatin 20 mg day1 for 4 weeks or no
intervention. Plasma samples taken at baseline and at the
end of the study were analyzed employing thrombin gen-
eration assay. Results and conclusions: The study
comprised 126 rosuvastatin users and 119 non-users.
Mean age was 58 years, 61% were men, 49% had unpro-
voked VTE and 75% had cardiovascular (CV) risk fac-
tors. Endogenous thrombin potential (ETP) increased
from baseline to end of study in non-statin users (mean
97.22 nM*min; 95% CI, 40.92–153.53) and decreased in
rosuvastatin users (mean 24.94 nM*min; 95% CI,
71.81 to 21.93). The mean difference in ETP change
between treatments was 120.24 nM*min (95% CI,
192.97 to 47.51), yielding a 10.4% ETP reduction by
rosuvastatin. The thrombin peak increased in both non-
statin (mean 20.69 nM; 95% CI, 9.80–31.58) and rosuvas-
tatin users (mean 8.41 nM; 95% CI 0.86 to 17.69). The
mean difference in peak change between treatments was
11.88 nM (95% CI, 26.11 to 2.35), yielding a 5% peak
reduction by rosuvastatin. Other thrombin generation
parameters did not change substantially. The reduction in
ETP and peak by rosuvastatin was more pronounced in
the subgroups of participants with CV risk factors and
with unprovoked VTE. We conclude that rosuvastatin
reduces thrombin generation potential in patients who
had VTE.
Keywords: hydroxymethylglutaryl-CoA reductase inhibitors;
randomized clinical trial; thrombin generation; thrombophilia;
venous thrombosis.
Introduction
Venous thromboembolism (VTE) contributes significantly
to the global disease burden and, therefore, preventive
measures and adequate treatment are warranted [1].
Anticoagulation is the treatment of choice for preventing
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VTE episodes [2]. Bleeding complications are a major
concern and may lead to treatment avoidance in many
cases [3]. The latter underscores the need for alternative
treatment options for VTE prophylaxis. Statins may pro-
vide a promising alternative treatment for thrombopro-
phylaxis because these drugs are alleged to have
pleiotropic effects on hemostasis and may reduce VTE
risk, although strong clinical evidence supporting these
effects is still scarce [4].
Previous studies have reported that statins reduce the
risk of first VTE by 14–54% [5–9] and the risk of recur-
rent VTE by 27% [10]. However, healthy user effects, sur-
vivor bias and adherence bias could have influenced these
results [11]. Moreover, the strongest evidence on the effect
of rosuvastatin on first VTE still comes from one ran-
domized clinical trial [8], whereas no randomized trials
have investigated the impact of statin therapy on the risk
of recurrent VTE. Despite the need for additional ran-
domized trials, the lack of knowledge on the mechanisms
that are the basis of the supposed causal association
between statin use and a reduced risk of VTE may dis-
courage the conduction of such interventional studies.
Recently, we have shown in the STAtins Reduce
Thrombophilia (START) trial that 1 month of treatment
with rosuvastatin at 20 mg day1 led to an improved
coagulation profile as compared with non-statin users in
patients with prior VTE, most notably by reducing factor
VIII plasma levels [12]. These observations from the
START trial were the first randomized evidence indicat-
ing that rosuvastatin reduces coagulation factor levels in
patients with prior VTE and confirmed similar findings
previously observed for other statins [13–15]. To better
understand the effect of rosuvastatin on individual pro-
thrombotic profiles, we evaluated here whether rosuvas-
tatin could interfere with thrombin generation, a global
coagulation test that reflects not only the coagulation
potential [16–18] of an individual but also predicts the
risk of a first and recurrent VTE [19–21].
Methods
Trial design
The START trial is a randomized, open label, controlled,
clinical trial conducted in the Netherlands that investi-
gated whether the coagulation profile in persons with a
history of VTE and not taking anticoagulants is improved
when using rosuvastatin. Details of the study design are
described elsewhere [12]. The study was undertaken in
accordance with the Declaration of Helsinki and Interna-
tional Conference on Harmonization guidelines for Good
Clinical Practice. All participants gave written informed
consent prior to participation. START was approved by
the Medical Ethics Committee of the Leiden University
Medical Center, Leiden, the Netherlands, and is registered
at www.clinicaltrials.gov as NCT01613794.
Participants
Participants were recruited at three anticoagulation clinics
in the Netherlands (Leiden, Hoofddorp and Rotterdam)
between June 2012 and January 2017. Individuals aged
18 years or older with confirmed symptomatic proximal
deep vein thrombosis or pulmonary embolism, were eligi-
ble for inclusion in the study if their physicians approved
the cessation of oral anticoagulant treatment. Exclusion
criteria were: current use of statins or lipid-lowering
drugs, or any contraindications for rosuvastatin at
20 mg day1 as provided in the instruction leaflet from
the manufacturer.
Intervention
Informed consent was obtained at the study baseline visit.
The study baseline visit was defined at the time of the last
regular visit of the patient to the anticoagulation clinic.
After informed consent, participants were screened for
acquired risk factors for thrombosis through a question-
naire and tested for liver and kidney functions. At ran-
domization, participants were allocated to receive either
rosuvastatin at 20 mg day1 or no study medication. The
random allocation sequence was implemented by a central
telephone and the sequence was concealed until interven-
tions were assigned.
The duration of the study was 28 days, based on the
consideration that some small non-randomized studies
showed beneficial effects of statins on the coagulation sys-
tem as early as after 3 days of statin administration [12].
Measurements
Patients stopped using their vitamin K antagonist for
1 month (to allow the anticoagulant drugs to wear off),
after which a blood sample was drawn at the randomiza-
tion visit and at the end of the study period (i.e. 28 days
later). All blood draws were performed between 08:00
and 15:00. Blood was collected in tubes containing
sodium citrate (3.2%) and centrifuged within 3 h of
venepuncture at 2500 g for 15 min at 18 °C, after which
plasma was immediately stored at 80 °C. Laboratory
technicians, who were unaware of which participants were
rosuvastatin users, performed the assays after all partici-
pants had completed the study.
The thrombin generation potential was assessed by
means of the thrombin generation assay (TGA), which is
a global coagulation test that reproduces the kinetics of
thrombin formation [22,23], using the Calibrated Auto-
mated Thrombogram (Diagnostica Stago, Asineres,
France) according to the manufacturer’s specifications
[24]. Briefly, plasma samples were mixed with the assay
reagents (tissue factor and phospholipids) and tested in
duplicate. As internal control, normal pooled plasma,
derived from citrated plasma from 64 healthy men and
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women not taking oral contraceptives, was tested in each
assay and a thrombin calibrator was used for each plasma
duplicate. The fluorescent signal representing generated
thrombin was monitored in a Fluoroskan Ascent fluo-
rometer (Thermo Scientific, Waltham, MA, USA) and the
parameters were calculated with the Thrombinoscope
software (Thrombinoscope BV, Maastricht, the Nether-
lands). The TGA parameters determined were: endoge-
nous thrombin potential (ETP), thrombin peak, time to
peak, lag time and velocity index. ETP, or area under
curve, represents the total amount of thrombin generated
over time. The thrombin peak represents the maximum
amount of thrombin that can be generated. Time to peak
indicates the time required to reach the maximum amount
of thrombin formed. The lag time measures the length of
time between the start of the assay (addition of triggers)
and the initiation of thrombin generation. The velocity
index is defined as [peak height/(time to peak  lag time)]
and represents the rate of thrombin generation [20].
Outcomes
Because the ETP and thrombin peak have been consis-
tently associated with VTE risk [25–31], the primary end-
points were defined as the difference in change in ETP
and thrombin peak from baseline to the end of the study
between rosuvastain users and non-users. The differences
in the change in lag time, time to peak or velocity index
were considered secondary endpoints. The study was orig-
inally powered on factor VIII [12]. Nevertheless, we
observed in the non-statin users that the mean ETP was
1245 mM*min (SD 322) at randomization. Therefore, we
a priori expected to find a powered mean difference of at
least 76 nM*min or 6% decrease between participants at
the end of the study with a two-sided alpha of 0.05 and
80% power.
Statistical analysis
Final analyses were carried out by modified intention-to-
treat because there were post-randomization exclusions.
The mean levels and 95% confidence intervals (95% CIs)
of all prespecified thrombin generation assay parameters
were calculated at the time of randomization (baseline),
at the end of the study period and for the change between
these two time periods within each treatment group. We
also calculated the percentage of change within groups by
subtracting the baseline value from the end of the study
value, dividing it by the baseline value and multiplying
the result by 100%.
To determine the between-groups difference in throm-
bin generation parameters, the mean difference in change
and 95% CI between treatment groups (rosuvastatin users
vs. non-users) was calculated by means of linear regres-
sion methods. We performed both unadjusted and age
and sex-adjusted analyses, because more men were
randomized to non-rosuvastatin use and non-rosuvastatin
users were slightly older than those who were randomized
to rosuvastatin. In a predefined sensitivity analysis, we
excluded all participants who reported signs or symptoms
of an infection during the study, as infections may affect
thrombin generation [32,33].
Next, we plotted the end-of-study-expected and the
end-of-study-observed thrombin generation among rosu-
vastatin users. To do so, we assumed that if patients
assigned to rosuvastatin had not received the drug, they
would have had the same change in thrombin generation
as those assigned to non-statin treatment. Thus, the
expected end-of-study thrombin generation among rosu-
vastatin users was estimated by adding the mean change
in thrombin values (at each time-point of the thrombin
generation curve) within non-statin users to the corre-
sponding baseline thrombin value in rosuvastatin users.
Additionally, we performed a subgroup analysis
according to the following potential or established prog-
nostic determinants of recurrent venous thrombosis:
male/female sex, unprovoked/provoked first event, deep
vein thrombosis or pulmonary embolism, and presence or
absence of self-reported cardiovascular risk factors.
A post hoc analysis was performed to investigate
whether the coagulation factors VIII, VII, XI and
D-dimer were associated with the effect of rosuvastatin
on ETP. For this purpose, we performed linear regression
with those coagulation factors entered as independent
variables, along with the randomization groups and sex
and age, and ETP entered as dependent variable. All
analyses were performed with SPSS version 23.0 (SPSS
Inc, Chicago, IL, USA).
Results
Study population
A total of 255 patients were randomized between Decem-
ber 2012 and December 2016, 131 were assigned to
receive rosuvastatin and 124 were allocated to non-statin
treatment. Figure 1 shows the trial profile. Two partici-
pants allocated to rosuvastatin treatment did not start
treatment and another six randomized, three in each
study arm, did not complete the study. The thrombin
generation assay could not be performed in two patients
because of technical issues; they both had been assigned
to non-statin treatment. Table 1 presents baseline charac-
teristics in the 245 participants who completed the study:
126 assigned to rosuvastatin and 119 assigned to non-
rosuvastatin treatment.
Non-rosuvastatin users were slightly older than rosu-
vastatin users; the mean ages were 58.4 years (range 21–
80) and 56.8 years (range 19–82), respectively. More men
were assigned to non-statin treatment; the proportion of
men was 54% among rosuvastatin users and 69% among
non-users. Other reported exposures, such as body mass
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index (BMI), type and classification of venous throm-
boembolism, and presence of cardiovascular risk factors,
were balanced at baseline (Table 1).
Outcomes
Results of all measured thrombin generation parameters
are shown in Table 2. ETP increased 7.8% from baseline
to end of study in non-statin users (mean change, or
intraindividual variability, within non-users,
97.22 nM*min; 95% CI, 40.92–153.53) and decreased
1.9% from baseline to end of study in rosuvastatin users
(mean change in rosuvastatin users, 24.94 nM*min; 95%
CI, 71.81 to 21.93). The mean difference between treat-
ments, after adjustment for age and sex, was
120.24 nM*min (95% CI, 192.97 to 47.51). After the
exclusion of patients who reported an infection at the end
of the study, as prespecified by the study protocol, the
age and sex-adjusted mean difference in ETP between
treatments was 129.39 nM*min (95% CI, 202.29 to
56.49). The mean difference between treatments yielded
a treatment effect of 10.4% (95% CI, 4.5–16.2%) reduc-
tion in ETP by rosuvastatin, when compared with non-
statin treatment (Fig. 2).
Although the thrombin peak increased in both rosuvas-
tatin and non-statin users from baseline to the end of the
study, the percentage change was higher for non-users
(7.6%) relative to the rosuvastatin users (2.9%). The
mean change in thrombin peak was 20.69 nM (95% CI,
9.80 to 31.58) for the non-users and 8.41 nM (95% CI,
0.86 to 17.69) for the rosuvastatin users, which resulted
in a mean difference in change between both treatments,
adjusted for age and sex, of 11.88 nM (95% CI, 26.11
to 2.35). The mean difference between the treatments
yielded a treatment effect of 5.0% (95% CI, 0.2 to
10.2%) reduction in thrombin peak by rosuvastatin, when
compared with non-statin treatment (Fig. 2).
The time to peak decreased 6.4% from baseline to the
end of the study in rosuvastatin users (mean change,
0.28 min; 95% CI, 0.35 to 0.21), and 1.5% in non-
statin users (mean change, 0.07 min; 95% CI, 0.23 to
0.09). The mean difference in these changes between treat-
ments was 0.21 min (95% CI, 0.38 to 0.03), which
was equivalent to a treatment effect of 4.8% (95% CI,
0.9–8.5) reduction in time to peak by rosuvastatin, when
compared with non-statin treatment (Fig. 2). The results
were not materially affected by excluding the eight partic-
ipants who reported an infection. Changes in lag time
and velocity index were not different between treatments
(Fig. 2).
Figure 3 illustrates the difference between expected and
observed thrombin generation in rosuvastatin users by
the end of the study.
Tables S1–S5 show all measures of thrombin genera-
tion parameters in the subgroups of sex, unprovoked or
provoked first VTE, deep vein thrombosis or pulmonary
Assessed for eligibility
(n = 4293)
Excluded (n = 4038)
Randomized
(n = 255)
Allocated to rosuvastatin
(n = 131)
Lost to follow-up (n = 0)
Study drug not started (n = 2)
Discontinued
- Withdrawn consent (n = 0)
- Recurrent venous thrombosis (n = 2)
- Other serious adverse event* (n = 1)
- Death (n = 0)
- Technical failure (n = 0)
Allocated to non-statin treatment
(n = 124)
Lost to follow-up (n = 0)
Discontinued
- Withdrawn consent (n = 1)
- Recurrent venous thrombosis (n = 2)
- Other serious adverse event (n = 0)
- Death (n = 0)
- Technical failure (n = 2)
Completed study as intended (n = 126) Completed study as intended (n = 119)
- Not meeting inclusion criteria (n = 2360)
- Declined to participate (n = 1678)
Fig. 1. Trial profile. Study enrolment, randomization, follow-up and reasons for withdrawal (*one participant admitted to hospital with a diag-
nosis of acute asthma exacerbation).
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embolism, and presence or absence of self-reported car-
diovascular risk factors. These subgroup analyses revealed
that the decrease in ETP and thrombin peak by rosuvas-
tatin was more pronounced in patients with unprovoked
venous thrombosis, pulmonary embolism or cardiovascu-
lar risk factors, than in those with provoked venous
thrombosis, deep vein thrombosis or without cardiovascu-
lar risk factors (Fig. 4). A relative decrease in ETP fol-
lowing rosuvastatin use was also more pronounced in
men than in women, whereas the effects of rosuvastatin
on thrombin peak were similar between the sexes. Sub-
group analysis of the effect of rosuvastatin on other
thrombin generation parameters revealed similar results
as in the main analysis.
As we have recently reported that treatment with rosu-
vastatin led to a decrease in the levels of D-dimer and
coagulation factors VIII, VII and XI as compared with
non-statin in START, we performed a post hoc analysis
to evaluate whether the observed effect of rosuvastatin on
thrombin generation could be explained by the levels of
these factors at the end of the study. As shown in
Table 3, the effect of rosuvastatin on thrombin generation
was reduced by 33% with factor VII, but not by the other
coagulation factors/D-dimer. T
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Table 1 Baseline characteristics of participants
Rosuvastatin users
(n = 126)
Non-users
(n = 119*)
General
Age (years) 56.8 (19–82) 58.4 (21–80)
Male 68 (54) 82 (69)
Body mass index (kg m2) 27.4 (19.2–43.5) 27.7 (17.2–43.3)
Aspirin use 5 (4) 5 (4)
Venous thrombosis characteristics
Type of venous thromboembolism
Deep vein thrombosis 72 (57) 64 (54)
Pulmonary embolism 54 (43) 55 (46)
Unprovoked 57 (45) 62 (52)
Provoked, by 69 (55) 57 (48)
Surgery/trauma/
immobilization
32 (25) 30 (25)
Travel >4 h 22 (18) 14 (12)
Estrogen use (% in
women)
24 (41) 14 (38)
Pregnancy/puerperium
(% in women)
0 (0) 2 (5)
Malignancy 2 (2) 8 (7)
Recurrent venous
thrombosis
10 (8) 8 (7)
Cardiovascular risk factors
Cardiovascular risk 89 (71) 94 (78)
Current smoking 18 (14) 16 (13)
Hypertension 24 (19) 20 (17)
Diabetes 3 (2) 0 (0)
Overweight† 54 (43) 51 (43)
Obesity‡ 29 (23) 34 (28)
Continuous variables denoted as mean (range), categorical variables
as n (%). *Technical issues in two non-users. †Overweight was
defined as body mass index (BMI) between 25 and 30 kg m2.
‡Obesity was defined as BMI above 30 kg m2.
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Discussion
In this randomized clinical trial (START), we have
shown that treatment with rosuvastatin leads to a relative
reduction in thrombin generation potential, decreasing
the ETP by 10.4% (adjusted mean difference between
treatments, 129.39 nM*min) and decreasing the throm-
bin peak by 5% (adjusted mean difference between treat-
ments, 13.69 nM), in comparison with non-statin
treatment. Our results confirm previous clinical studies
that also demonstrated that statin therapy, either with
rosuvastatin [30], simvastatin [34], atorvastatin [35,36] or
cerivastatin [37], affects coagulation factors and thrombin
generation.
Additionally, these findings are consistent with previous
results from the START trial, in which rosuvastatin treat-
ment was shown to decrease the plasma factor VIII levels
by 6% (adjusted mean difference in change between treat-
ments, 8.2 IU dL1; 95% CI, 13.6 to 2.9) and those
of FXI by 4% (adjusted mean difference in change
between treatments, 4.9 IU dL1; 95% CI, 9.9 to 0.1),
coinciding with a decrease in D-dimer by 3% and factor
VII levels by 4% [12]. The results from the START trial
point to the same direction of an effect of rosuvastatin on
the individual coagulation profile, but the observed
decrease in thrombin generation potential was only par-
tially mediated by factor VII and by D-dimer, factor VIII
or XI. Because thrombin generation is a product of a syn-
ergic combination of multiple coagulation factors [18,38],
it is possible that the mechanism behind the effect of
rosuvastatin on decreasing thrombin generation potential
relies on the reduction of several coagulation factors,
some of them not measured in the START trial. Whether
this effect of rosuvastatin on the coagulation profile has
clinical significance in terms of reducing VTE risk
deserves to be addressed in clinical trials that aim to eval-
uate this question. However, it is possible to speculate on
a potential clinical impact of statins on VTE risk if the
current findings are evaluated in the light of previous
studies. Studies on thrombin generation and VTE risk
have demonstrated that both the ETP and thrombin peak
are associated with a first VTE [16,28,29,31] and can pre-
dict the risk of recurrent VTE [25–27,30].
A cohort study of 188 patients with VTE [28] reported
that the risk of recurrent VTE increased by 25% per
100 nM*min increase in ETP (hazard ratio, 1.25 per
100 nM*min increase; 95% CI, 1.01–1.55). The Austrian
Study on Recurrent Venous Thromboembolism
(AUREC), which is a cohort study with patients with an
unprovoked first episode of VTE, showed that the risk of
recurrent VTE increased by 1.4% for each 1% increase in
ETP (hazard ratio 1.014 per 1% increase in ETP; 95%
CI, 1.0–1.03; P = 0.06) [25]. Another study derived from
the AUREC cohort showed that the relative risk of recur-
rent VTE increased by 4% (relative risk [RR], 1.04; 95%
CI, 1.02–1.06) for each 10 nM increase in thrombin peak
[27]. The Vienna Cancer and Thrombosis Study (CATS),
a prospective cohort study of patients with cancer,
demonstrated that patients who developed VTE had 10%
higher thrombin peak at baseline than those without VTE
events (peak values 556 nM, 95% CI 432–677 and
499 nM, 95% CI 360–603, respectively) [39]. Considering
ETP and thrombin peak as surrogate markers of recur-
rent VTE risk, as described in the aforementioned trials,
our results suggest that rosuvastatin has the potential to
decrease the risk of recurrent VTE by 14–25%. Interest-
ingly, a meta-analysis of observational studies reported
that statins reduced the overall risk of recurrent VTE by
27% (RR, 0.73; 95% CI, 0.68–0.79) [10]. Therefore, our
finding that statins are capable of modulating the pro-
thrombotic profile in patients after a first VTE episode
could be interpreted as statins having the potential to
decrease the risk of recurrence.
We also observed that the relative treatment effect of
rosuvastatin on ETP was mainly driven by the absence of
an increase in this parameter among rosuvastatin users,
in contrast to a significant increase in ETP in patients not
using statins. This is consistent with a previous observa-
tion from this trial demonstrating that the difference in
D-dimer levels between the treatment groups was driven
by the absence of an increase in D-dimer following
rosuvastatin use [12]. As both thrombin generation and
D-dimer are markers of hypercoagulability [25,26], the
current results provide further evidence that rosuvastatin
may prevent a rebound phenomenon; that is, a shift to a
more procoagulant profile along with increased risk of a
recurrence of VTE after the sudden withdrawal of antico-
agulant treatment [40,41]. Preventing such a rebound
hypercoagulability may be a further benefit to patients
with previous VTE in whom anticoagulation is with-
drawn.
It is worth noting that the decrease in ETP and throm-
bin peak appeared strongest in participants with
Endogenous thrombin
Thrombin peak
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Fig. 2. Relative effect of rosuvastatin treatment on thrombin genera-
tion. This figure illustrates the changes in endogenous thrombin
potential, from baseline to the end of treatment, compared between
rosuvastatin users and non-statin users.
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unprovoked VTE and in those with cardiovascular risk
factors. This potential benefit for patients who had
unprovoked VTE is interesting because these patients are
at high risk of recurrent VTE [2], and anticoagulants
may not be prescribed if a patient is considered to be at
high risk of anticoagulation-related bleeding [42]. Second-
ary prevention with statin therapy may be a convenient
alternative treatment, as statins do not increase the risk
of bleeding complications [43]. In addition, a benefit
among patients with cardiovascular risk factors is note-
worthy because most of these patients are already likely
to receive statins [44]. Therefore, the possibility of using
one single drug to prevent both cardiovascular diseases
and VTE could diminish the medication burden associ-
ated with the use of several classes of drugs and decrease
the risk of adverse effects, thus increasing the changes in
treatment efficacy [45].
Although our results point to a decrease in thrombin
generation potential by rosuvastatin, not all thrombin
generation parameters were modified after the treatment.
The lag time and velocity index did not change substan-
tially, whereas the time to peak decreased in rosuvastatin
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Fig. 3. Thrombin generation curves: (A) mean values of thrombin generation over time in non-statin users at baseline and at the end of the
study, (B) mean values of thrombin generation over time in rosuvastatin users at baseline and at the end of the study, and (C) expected mean
thrombin generation values (if rosuvastatin would not have a treatment effect on thrombin generation) and observed mean thrombin genera-
tion values by the end of the study in patients receiving rosuvastatin.
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users, in comparison with non-statin users. Despite the
fact that a reduced time to peak may indicate a hyper-
coagulable state [20], the real significance of this parameter
is not known, because it is not associated with the risk of
VTE. Conversely, as time to peak is calculated based on the
thrombin values, a shortened time to peak may be explained
by a relative reduction in ETP and thrombin peak [46]; a
similar phenomenon was reported in a previous study,
wherein a protraction of the thrombin generation curve
lengthened the time to peak [47].
There are some aspects of this study that need to be
highlighted. First, the trial was not blind to the partici-
pants and physicians involved; however, it was considered
unlikely that knowledge of the treatment could affect a
surrogate laboratory outcome. Second, we previously
noticed that the distribution of sex and age after random-
ization was different between the groups, and we a priori
decided to adjust the analysis for these potential con-
founding factors [12]. These adjustments did not influence
our results. Third, we decided a priori to perform a sensi-
tivity analysis excluding participants who developed an
infection during the follow-up because of the possibility
of an acute-phase reaction affecting the thrombin genera-
tion potential, which did not materially change the
results. Fourth, although the results from our subgroup
analyses suggest that statins may have the strongest
potential to decrease thrombin potential in individuals
with CV risk factors or unprovoked VTE, these subgroup
analyses must be handled with caution as the study was
not designed or powered to analyze differences in sub-
groups [48]. Finally, the assessment of thrombin genera-
tion potential is dependent on the assay conditions, which
vary according to different laboratory protocols and may
affect the clinical interpretation of the results [49]. Besides
the potential limitations, the START trial evaluated the
effect of rosuvastatin on six coagulation parameters
related to the risk of VTE: VWF, factors VIII, VII and
XI, D-dimer, ETP and thrombin peak. The values of all
parameters were consistently pointing towards a
decreased level with rosuvastatin treatment, as compared
with no statin. Altogether, these results confirm that rosu-
vastatin is capable of affecting several components of
coagulation and modifying the coagulation profile of
patients with a prior VTE.
We conclude that rosuvastatin 20 mg day1 improves
the coagulation profile in patients with VTE by reducing
the thrombin generation potential after anticoagulation
withdrawal. These results of the START trial suggest that
statin therapy might be beneficial in patients at risk of
recurrent VTE and provide a clinical rationale for the
conduction of a randomized controlled trial to evaluate
the effectiveness of rosuvastatin in decreasing the risk of
recurrent VTE.
Addendum
F. A. Orsi performed the statistical analyses and
drafted the manuscript. J. S. Biedermann performed the
statistical analyses and revised the manuscript. M. J. H.
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Fig. 4. Relative effect of rosuvastatin treatment on thrombin generation
potential by subgroups. The relative effect of rosuvastatin treatment on
endogenous thrombin potential (A) and on thrombin peak (B) in prespec-
ified subgroups: sex (female/male), type of VTE (DVT/PE), VTE classifi-
cation (provoked/unprovoked) and presence of cardiovascular (CV) risk
factors (no CV risk/CV risk) compared with non-statin treatment.
Table 3 Mean difference in endogenous thrombin potential between
rosuvastatin users and non-users (reference) at the end of the study,
adjusted for coagulation factors
Mean difference (95% CI)‡
ETP (nM*min) at the end of the study
No coagulation factor 89.46 (153.18, 25.74)
+Factor VIII 87.66 (148.43, 26.89)
+Factor XI 73.13 (133.58, 12.68)
+Factor VII 59.93 (120.02, 0.17)
+DD 87.20 (151.41, 22.99)
+Factors VIII, XI, VII, DD 54.98 (111.99, 2.03)
DD, D dimer; CI, confidence interval. ‡Comparison between rosu-
vastatin treatment and no treatment at the end of the study, adjusted
for age and sex.
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